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Summary Cancer mortality data reflect disease incidence and the effectiveness of treatment. Incidence data,
however, reflect the burden of disease in the population and indicate the need for prevention measures,
diagnostic services and cancer treatment facilities. Monitoring oftargets mandates that both be considered. The
Scottish Cancer Target, established in 1991, proposed that a reduction of 15% in mortality from cancer in the
under-65s should be achieved between 1986 and 2000. Each year in Scotland approximately 8300 persons under
65 are diagnosed with cancer and 4500 die from the disease. The most common malignancies, in terms of both
incident cases and deaths, in the under-65s, are lung and large bowel cancer in males, and breast, large bowel
and lung cancer in females. A decrease of 6% in the number of cancer cases diagnosed in males under 65 is
predicted between 1986 and 2000, whereas the number of cases in females in the year 2000 is expected to
remain at the 1986 level. In contrast, substantial reductions in mortality are expected for both sexes: 17% and
25% in males and females respectively. Demographic changes will influence the numbers of cancer cases and
deaths in the Scottish population in the year 2000. However, long-term trends in the major risk factors, such as
smoking, are likely to be the most important determinants of the future cancer burden.
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The Scottish health targets were established in 1991 in Health
Education in Scotland-A National Policy Statement (SHHD,
1991) and reiterated in Scotland's Health-A Challenge to Us
All (SHHD, 1992). Among targets pertaining to the major
causes of morbidity and mortality in the Scottish population
was one directed specifically towards cancer: 'to reduce
mortality from cancers in the under-65s by 15% between
1986 and 2000', that is, a reduction from 104 deaths per
100 000 to 88 deaths per 100 000 by the year 2000.
Since the last century information on cause of death has
been recorded routinely by the Registrar General for
Scotland and used to monitor trends in mortality from
cancer. However, to assess the burden of disease it is
necessary to be able to measure cases newly diagnosed in
the population. Scotland is fortunate in that it is one of the
few countries in the world with long-standing, national,
population-based cancer registration. The Scottish National
Cancer Registration Scheme aims to collect information on
all incident cases of cancer in Scotland and has a database
extending back to 1958. The availability of these long series
of data provides an opportunity to estimate cancer incidence
and mortality in future years. The purpose of this paper is to
facilitate the assessment of progress towards attaining the
Scottish Cancer Target by describing trends in incidence of,
and mortality from, the common cancers over recent decades
and presenting projected numbers of cases and deaths in the
year 2000.
Data and methods
Registrations of cancer (ICD-9 140-208) in the period
1968-92 were extracted from the national cancer database
held by the Information & Statistics Division of the National
Health Service in Scotland. Non-melanoma skin cancer
(ICD-9 173) registrations were excluded as they are unlikely
to be complete. With the permission of the General Register
Office (Scotland), individual mortality records for 1968-92
with cancer recorded as the primary cause of death were
extracted from computerised death listings.
A statistical model based on birth cohort, age and time
period (Robertson and Boyle, 1986) was used to estimate the
projected number of cancer registrations and deaths in
Scotland in the year 2000. This method partially addresses
the problem of overlapping birth cohorts by using individual
cancer registration and mortality records to assign each
individual to a unique cohort. Records were tabulated by
period of diagnosis (or death) (1968-72, 1973-77,...,
1988-92), age at diagnosis (or death) (25-29, 30-34,.
80-84) and birth cohort (1883-87, 1888-92, ... , 1963-67).
For each cancer site included in the analysis, a log-linear
model was fitted in GLIM (NAG, 1985), with adjustment for
extra-Poisson variation where necessary (Breslow, 1984), to
generate estimates of age, time period and birth cohort effects
for registration and mortality data separately. The age effects
represent differing risks associated with different age groups
and may reflect cumulative exposure to cancer causing
agents; the time period effects describe changes in rates
occurring in all age groups simultaneously and may reflect,
for example, increasing completeness of registration or the
introduction of a new diagnostic technique; the birth cohort
effects represent changes in rates in successive generations
and may reflect differences in lifestyle or cultural habits such
as reproductive practices or tobacco or alcohol consumption.
Only those sites of cancer for which at least 200 cases were
diagnosed in the age group 0-64 years in 1986 were included
in these analyses. Males and females were considered
separately. The individual cancers analysed were stomach
(ICD-9 151), large bowel (ICD-9 153 + 154), lung (ICD-9
162), and bladder (ICD-9 188) in males and large bowel
(ICD-9 153 + 154), lung (ICD-9 162), breast (ICD-9 174),
cervix uteri (ICD-9 180) and ovary (ICD-9 183) in females.
All malignant neoplasms (ICD-9 140-208, excluding ICD-9
173) were also considered as a single category.
It was assumed that the cancer registration and death rates
in the 0-24 age group in the period 1981-90 (Sharp et al.,
1993: Registrar General, 1981-90) would persist to the year
2000 and that the period effects for 1988-92 from the fitted
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models would continue in future periods. Estimates of age
and birth cohort specific incidence and mortality rates from
the fitted models were applied to population projections
(Registrar General, 1993) to produce projected numbers of
cases and deaths in the 0-64 age group. Percentage changes
between the model estimates for 1986 and 2000 were
calculated and applied to the actual 1986 registrations and
deaths to obtain projected numbers in the year 2000.
The results are presented in two sections. The first section
concerns cancer in Scotland in the baseline year 1986.
Numbers and percentages of the most common cancers in
the under 65 population are presented. Five year relative
survival rates were calculated as described by Black and co-
workers (1993) for patients aged under 65 and diagnosed in
two periods, 1968-72 and 1983-87. Incidence and mortality
rates for all malignant neoplasms in the under-65s in 1986,
directly standardised with respect to the world population
(Segi, 1960), were obtained from the EUROCIM package
(European Network of Cancer Registries, 1995) for Scotland
and selected European cancer registries. The second section
examines time trends in incidence and mortality and presents
the projected numbers of registrations and deaths in the year
2000. Both crude and age-standardised rates are used
depending on circumstances. To facilitate comparison with
the Scottish Cancer Target, which is expressed in terms of
unadjusted rates, crude incidence and mortality rates for
individual cancer sites in 1986 and 1992 are shown. To permit
assessment of long-term time trends in incidence and
mortality, age-standardised rates (to the world population)
for the period 1960-1992 were derived from Black et al.
(1995). These data are presented for all malignant neoplasms
combined as well as for individual cancer sites.
Results
Cancer in Scotland in the baseline year 1986
Incidence In 1986, 10 795 males and 11 109 females of all
ages were registered with cancer (non-melanoma skin cancer
excluded) in Scotland. Of this total, 38% (8313) of cases
occurred in those aged under 65 years, 56% (12 190) in the
65 to 84 age group and the remaining 6% (1401) in those
aged 85 and older. The proportion of cancers presenting
before 65 years in females (40%: 4452 registrations) was
greater than that in males (36%: 3861) due, in the main, to
cancer of the reproductive system in females.
The numbers and percentages of registrations for the most
frequent cancers in persons under 65 years of age in 1986 are
shown in Table I. In males, cancer of the lung accounted for
the greatest proportion of registrations (28%), followed by
cancers of the large bowel (11%) and bladder (7%). In
females, 31% of registrations were due to breast malignancies
with a further 14% due to cancers of the cervix and ovary.
Cancers of the lung and large bowel were also common (12%
and 9% respectively).
Mortality Almost a third (4539) of all cancer deaths
occurred in those aged under 65 years, a further 60%
(8758) in the 65-84 age group and 8% (1194) in those aged
85 and older. Lung tumours accounted for 40% of cancer
deaths in males and 20% in females (Table I). In total 41%
of deaths in females under 65 were ascribed to cancers of the
reproductive system.
Survival Relative survival rates at five years after diagnosis
for all cancer patients under 65 years diagnosed in 1983-87
Table H Five year relative survival rates (%) for persons aged
under 65 at diagnosis, by site of cancer, sex and period ofdiagnosis,
1968-72 and 1983-87
Period ofdiagnosis
Site ofcancer 1968-72 1983-87
Males
Stomach (ICD-9 151) 7.9 12.2
Large bowel (ICD-9 153 + 154) 34.1 41.0
Lung (ICD-9 162) 10.1 8.6
Bladder (ICD-9 188) 63.9 76.3
All malignant neoplasms 25.0 33.0
(ICD-9 140 -208)a
Females
Large bowel (ICD-9 153+ 154) 37.3 42.3
Lung (ICD-9 162) 8.7 9.0
Breast (ICD-9 174) 56.8 66.3
Cervix (ICD-9 180) 59.6 64.2
Ovary (ICD-9 183) 28.9 37.9
All malignant neoplasms 42.9 49.4
(ICD-9 140 -208)a
aExcludes non-melanoma skin cancer (ICD-9 173).
Table I Numbers and percentages of registrations of, and deaths from, the most common cancers in persons aged under 65, by sex and site of
cancer, 1986
No. of No. of
Site ofcancer registrations % deaths %
Males
Lung (ICD-9 162) 1064 27.6 941 40.2
Large bowel (ICD-9 153+ 154) 437 11.3 211 9.0
Bladder (ICD-9 188) 277 7.2
Stomach (ICD-9 151) 229 5.9 137 5.9
Testis (ICD-9 186) 150 3.9
Oesophagus ICD-9 150) 125 5.3
Brain and central nervous system (ICD-9 191 + 192) 97 4.1
Other sites 1704 44.1 830 35.5
All malignant neoplasms (ICD-9 140-208)a 3861 100.0 2341 100.0
Females
Breast (ICD-9 174) 1366 30.7 571 26.0
Lung (ICD-9 162) 527 11.8 452 20.6
Large bowel (ICD-9 153+ 154) 389 8.7 196 8.9
Cervix (ICD-9 180) 334 7.5 105 4.8
Ovary (ICD-9 183) 269 6.0 157 7.1
Other sites 1567 35.2 717 32.6
All malignant neoplasms (ICD-9 140-208)a 4452 100.0 2198 100.0
aExcludes non-melanoma skin cancer (ICD-9 173).Progress Towards the Scottsh Cancer Target
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was 33% for males and 49% for females (Table II). With the
exception of lung cancer, survival from most common
cancers improved between 1968-72 and 1983-87 (Table II).
International comparisons Table III shows age-standardised
incidence and mortality rates for all malignant neoplasms in
Scotland and selected European cancer registries in 1986.
Incidence and mortality in both sexes in Scotland belonged
towards the top of the range of rates reported across Europe.
The incidence of malignant neoplasms in Scottish males and
females aged under 65 exceeded that in England and Wales
by some 19% and 10% respectively. There were smaller
differentials between the countries in mortality; rates were
15% and 6% higher in Scottish males and females
respectively.
Trends in the common cancers and projected registrations and
deaths
All malignant neoplasms (ICD-9 140-208, excluding 173)
Since 1960 there have been steady increases in the age-
standardised incidence of all malignant neoplasms in persons
of both sexes aged under 65 in Scotland (Figure 1). Rates in
males rose by 17% from 122 per 100 000 in 1960 to 143 per
100 000 in 1992 and those in females by 43% from 120 to
172. For both sexes, the most substantial increases in
incidence were observed in those aged 55-64 years at
diagnosis (data not shown). Over the same time period,
cancer mortality in males declined consistently, from 99 to 77
per 100 000, whereas mortality in females remained constant
at around 75 per 100 000.
Table m Age-standardiseda incidence and mortality rates (per
100000), all malignant neoplasmsb, 0-64 years, Scotland and
selected European cancer registries, 1986
Incidence Mortality
Country and registry Males Females Males Females
Scotland 141.5 155.7 84.4 73.5
Denmark 131.8 171.1 76.2 77.7
Netherlands: south 131.3 145.8 76.8 63.6
Spain: Tarragona 118.7 116.5 73.1 51.8
England and Wales 118.7 141.8 73.5 69.3
Poland: Cracow 118.6 119.8 90.5 49.1
aWorld standard population. bExcludes non-melanoma skin cancer
(ICD-9 173).
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Figure 2 Crude incidence rates (per 100000) by site of cancer,
sex and year of diagnosis, 0-64 years, 1986 (U) and 1992 (E1).
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Figure 1 Age-standardised* incidence (O, males; 0, females)
and mortality rates (*, males; 0, females) (per 100000), by year
and sex, all malignant neoplasms, 0-64 years, 1960-92. *World
standard population.
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sex and year of death, 0-64 years, 1986 (U) and 1992 (Oi).
Table IV Actual and projected numbers of registrations and estimated percentage changes from 1986 to 2000, for persons aged under 65 at
diagnosis, by site of cancer and sex
No. ofregistrations Projected registrations Estimated
1986 2000 % change
Site ofcancer Males Females Males Females Males Females
Stomach (ICD-9 151) 229 161 -30
Large bowel (ICD-9 153 + 154) 437 389 441 333 1 -15
Lung (ICD-9 162) 1064 527 650 362 -39 -31
Breast (ICD-9 174) 1366 1518 11
Cervix (ICD-9 180) 334 428 28
Ovary (ICD-9 183) 269 255 -5
Bladder (ICD-9 188) 277 255 -8
All malignant neoplasms 3861 4452 3641 4461 -6 0
(ICD-9 140-208)a
aExcludes non-melanoma skin cancer (ICD-9 173).
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Table V Actual and projected numbers of deaths and estimated percentage changes from 1986 to 2000, for persons aged under 65 at death, by
site of cancer and sex
No. ofdeaths Projected deaths Estimated
1986 2000 % change
Site ofcancer Males Females Males Females Males Females
Stomach (ICD-9 151) 137 84 -39
Large bowel (ICD-9 153+ 154) 211 196 188 139 -11 -29
Lung (ICD-9 162) 941 452 583 258 -38 -43
Breast (ICD-9 174) 571 451 -21
Cervix (ICD-9 180) 105 107 2
Ovary (ICD-9 183) 157 105 -33
Bladder (ICD-9 188) 52 47 -10
All malignant neoplasms 2341 2198 1943 1649 -17 -25
(ICD-9 140 -208)a
aExcludes non-melanoma skin cancer (ICD-9 173).
In 1986 the crude incidence rates of all cancers in those
under 65 were 176 per 100 000 in males and 204 per 100 000
in females (Figure 2). The rate for males was little changed by
1992, whereas incidence in women had risen by 11%.
Mortality in 1986 was 107 and 101 per 100 000 for males
and females respectively (Figure 3). By 1992 this had fallen
by 8% in males and 3% in females.
In comparison with the baseline year, 1986, the number of
cancers diagnosed in those under 65 years in Scotland in 2000
is forecast to fall by 6% to 3641 in males and increase
marginally (0.2%) to 4461 in females (Table IV). Substantial
decreases in deaths are projected with the total in males
falling by 17%, from 2341 to 1943, and in females by 25%,
from 2198 to 1649 (Table V).
Cancer ofthe stomach (ICD-9 151) Incidence and mortality
rates for stomach cancer in males under 65 have declined
steadily over the last three decades. In 1986, approximately
one-third ofthe incident cases and a quarter ofdeaths in males
occurred in those under 65. Crude mortality in 1992 (5 per
100 000) was 18% lower than in the baseline year, 1986. In the
years to 2000 the decrease in stomach cancer is expected to
continue; the projected number of registrations represents a
decrease of 30% on the 1986 figure. A fall of a similar
magnitude in the number ofdeaths isexpected (39%) with rates
decreasing in all but'the youngest age groups (data not shown).
Cancer of the large bowel (ICD-9 153 + 154) Incidence data
for large bowel cancer in those under 65 indicate a small, but
steady, increase over the past 30 years. Mortality has shown a
smaller, consistent, downward trend. For both sexes the
crude incidence and death rates changed little between 1986
and 1992. The projected number of cases of large bowel
cancer in persons under 65 in the year 2000 is 774,
comprising a rise of 1% in males and a fall of 15% in
females on the 1986 figures. For both sexes, substantial
decreases in mortality are anticipated; 11% in males and 29%
in females. Relative survival has improved over the past 15
years for both sexes with a proportionately greater rise in
males (Table II).
Cancer of the trachea, bronchus and lung (ICD-9 162) In
1986, in those aged under 65, there were 1591 registrations of,
and 1393 deaths from, lung cancer. This accounted for 19%
of all new cancers and 33% of cancer deaths. Mortality rates
for lung cancer in Scottish males under 65 have been
declining since the mid 1960s with incidence falling since
1980. Between 1986 and 1992 crude incidence and mortality
rates fell by 17% and 20% respectively. For females under
65, both age-standardised incidence and mortality rates have
shown a steady upward trend since 1960. The number of
incident cases in 1992 slightly exceeded that in 1986.
Decreases of 39% and 31% in the numbers of cases
diagnosed in males and females respectively are expected
between 1986 and 2000. Falls of a similar magnitude are
predicted from mortality data (38% and 43%) with the
greatest reductions expected to occur in the younger age
groups.
Cancer of the female breast (ICD-9 174) A significant
proportion of breast tumours develop in women aged under
65 (52%) and 44% of deaths occur in this age group.
Incidence of breast cancer has risen steadily since 1960, with
the number of incident cases diagnosed increasing substan-
tially between 1986 and 1992. Little changed has been
observed in mortality. In the year 2000, 1518 registrations
are projected, an 11% increase on the number in the baseline
year. The rise comprises, in the main, an increase in the
numbers of tumours in women aged 50-64. It is predicted
that the numbers of deaths due to cancer of the breast in
those under 65 will fall by 21% between 1986 and 2000.
Cancer of the cervix uteri (ICD-9 180) The majority of
cervical neoplasia are diagnosed in women aged less than 65
years (72%) and more than one-half of deaths occur in this
age group. A regular downward trend in age-standardised
mortality rates is apparent since the 1960s. There is no
consistent pattern in incidence over the past 30 years; rates
were lower in the 1970s than the previous decade but rose
from 1980 to 1990. By 2000, a substantial increase in the
numbers of invasive cancers of the cervix diagnosed in the
under 65s is forecast; 28% higher than the 1986 figure.
Numbers of deaths are predicted to be little changed from the
1986 total.
Cancer of the ovary (ICD-9 183) Ovarian cancer incidence
and mortality rates in the under-65s have diverged over the
last 15-20 years. While incidence has increased since 1960,
mortality has been falling since the mid-1970s. Around half
of ovarian malignancies and 40% of deaths occur in women
aged under 65. Both crude incidence and mortality rates were
similar in 1992 to the baseline year 1986. A small (5%)
decrease in the number of incident cases in the year 2000 is
forecast. However, a substantial decrease (33%) in numbers
of deaths is predicted with falls of the greatest magnitude in
younger women.
Cancer of the bladder (ICD-9 188) Approximately a third
of male bladder cancer cases are diagnosed in the under-65s,
but, as relative survival at five years after diagnosis exceeds
75%, only 17% of deaths occur in this age group.
Standardised registration rates for males have shown a
steady increase over the past 30 years although mortality
has remained fairly constant. There was little difference in
incidence or mortality rates between 1986 and 1992. Falls of
similar magnitude in both incidence and mortality are
expected in the year 2000; 8% and 10% decreases in cases
and deaths respectively.
Discussion
Predicted mortality and incidence in the year 2000 in those
under 65 years
A substantial reduction in the numbers of deaths due to
cancer in the population aged under 65 in Scotland is
predicted between 1986 and 2000. A total of 3592 cancer
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deaths in those under 65 is expected in the year 2000, deaths
in those under 65 is expected in the year 2000, representing
decreases of 17% (from 2341 in 1986 to 1943 in 2000) and
25% (2198 to 1649) in males and females respectively. On the
basis of these estimates, the Scottish Cancer Target, of a 15%
reduction in mortality in the under 65s between 1986 and
2000 (SHHD, 1991), will be attained. In contrast, over the
same time period, a 3% decrease in the number of newly
diagnosed cancer cases is forecast, comprising a fall of 6% in
males but little change in females. In 2000, in those aged less
than 65 years, a total of 8102 incident cancer cases are
predicted, 55% of these occurring in women.
Data for all malignant neoplasms are difficult to interpret
and may conceal divergent patterns for specific cancers. In
men, substantial falls in the numbers of cases of, and deaths
from, stomach and lung cancer can be expected. In women
under 65, a reduction in the number of lung neoplasms is also
anticipated. This is discussed more fully below. Women are
also expected to experience increases in the numbers of
diagnosed tumours of the cervix and, to a lesser extent,
breast. In contrast, mortality is predicted to remain
unchanged for cervical cancer and to decline for breast
cancer. Organised screening exists for these cancers (Warner
et al., 1993; Strong, 1986) and is expected to influence trends
in both incidence and mortality greatly.
The specific cancer sites examined in this paper account
for around 60% of diagnosed cases and deaths from all
malignant neoplasms in persons under 65 years in Scotland.
Over the 10 years from 1981 to 1990 the incidence rates of
some other cancers not examined in this paper have risen
significantly. Malignant melanoma, non-Hodgkin's lympho-
ma and testicular cancer have shown the greatest increases
in incidence (Sharp et al., 1993). For example, between 1981
and 1990 the numbers of malignant melanoma cases
diagnosed in the under-65s rose from 156 to 325 and the
numbers of non-Hodgkin's lymphomas doubled from 73 to
148. Substantial proportions of these cancers are diagnosed
in those aged less than 65. In women, in particular,
incidence rates of oesophageal and larynx cancer are also
rising, albeit to a lesser extent, but these cancers constitute
only a small proportion of all neoplasms in those under 65
years. In common with trends observed in other countries,
the incidence of tumours of the prostate in Scottish men has
been rising and is expected to continue to rise: around 14%
of cases are diagnosed in those aged under 65.
Features of the statistical model
The model used to generate the projected numbers of cases
and deaths incorporates the combined effects of age at
diagnosis (or death), period of diagnosis (or death) and birth
cohort. It is well established that such a model is likely to
produce a more accurate description of time trends in disease
than one based simply on linear extrapolation (Clayton and
Schifflers, 1987).
On occasion the trends predicted for incidence and
mortality may seem discrepant-as for large bowel cancer.
Such an event may reflect not only changes in the time-lag
between diagnosis and death but also birth cohort-specific
improvements in survival associated perhaps with earlier
stage tumours in recent generations. The observations for
large bowel cancer are not unique to Scotland. In the US,
mortality from colon cancer is rising significantly in black
males, with little change in black women and a fall in whites
of both sexes. Incidence rose significantly in both black and
white men and in black females between 1973 and 1990 yet
there was a significant drop for white men and women from
1986 to 1990 (Miller et al., 1993). Under such circumstances
age-period-cohort models are likely to describe the
underlying trends more accurately than cross-sectional data.
The estimates of the age, period and birth cohort effects
generated by the model are subject to errors which are, of
course, proportionately greatest for less frequent cancers.
Therefore, the site-specific estimates of percentage change in
incidence will be more robust statistically than those for
mortality. Also, the projections for the most common cancers
(e.g. male lung cancer, female breast cancer) are more reliable
than those for other sites.
The introduction of new diagnostic techniques or advances
in therapy for cancer may be assumed to represent period
effects if they occur in all age groups simultaneously.
However, it is difficult to predict future developments in
these areas and the model assumes that the period effect in
1988-92 will continue unchanged to 2000. Further, it is
unlikely that new diagnostic methods or treatments are, or
will be, introduced at the same time and to the same extent in
all age groups. For example, the Scottish Breast Screening
Programme (SBSP) offers mammography to women aged
50-64 years (Warner et al., 1993). Although the long-term
aim of the screening programme is to reduce mortality by
25% in the screened age group by the year 2000, in the short
term incidence should rise. The magnitude of this rise is
difficult to quantify and has not been incorporated in the
statistical model. Therefore, it is likely that the incidence
model will over-estimate to some extent the number of new
cases of breast cancer in 2000. However, since the SBSP
achieved national coverage in 1991, the mortality model
describes the trends likely to occur in the absence of
systematic screening. Thus, the prediction of a decrease of
21% in the number of deaths due to cancer of the breast in
women under 65 between 1986 and 2000 may under-estimate
the actual reduction achieved should screening prove
effective. The combined effect of long-term trends in
mortality and the introduction of national breast screening
cannot be quantified as it is, as yet, too early to formally
evaluate the screening programme.
Cytological screening for cervical cancer, aimed at
detecting lesions in the preclinical phase, has been offered
on a systematic basis in some parts of Scotland for more than
30 years (Macgregor et al., 1994). Screening policies have
varied across the country and over time. Consequently, the
effects of cervical screening on the statistical models for both
incidence and mortality are likely to be complex and cannot
be adequately assessed.
Trends in cancer risk factors
For many of the cancers diagnosed in Scotland the risk
factors are well understood. Muir (1993) estimates that at
least one-third of all tumours in males and 17% in females
are probably caused by smoking and a further 6% and 3%
caused by the combined effects of tobacco and alcohol. As
tobacco consumption, in particular, is implicated in the
aetiology of many of the cancers common in Scotland, past
and current patterns of tobacco use in the population will
dictate a large part of future cancer incidence and mortality
trends. From 1960 to 1980 the incidence of cancer of the lung
rose steadily in Scottish men; since that time both incidence
and mortality rates have been declining. For women a
consistent upward trend was still apparent into the 1990s
(ISD, 1994). These data reflect the very strong birth cohort
effect in lung cancer (Black et al., 1995) related to patterns of
smoking behaviour in successive generations. For men the
peak incidence occurred when the birth cohorts and age
groups of highest risk coincided at the end of the 1970s. As
smoking became prevalent among women some years later
than in men, it is predicted that incidence will not peak until
around 2000. Data on tobacco use in Scotland (ISD, 1994)
reveal that the decline in smoking prevalence in women,
notably younger women, has been less pronounced than in
men. This may mean that the future decreases in lung cancer
incidence and mortality in younger women will not be of the
magnitude forecast in this paper.
The proportions of neoplasms in the Scottish population
likely to be caused by aspects of lifestyle, including diet and
reproductive factors, have been estimated to be 32% in males
and 61% in females (Muir, 1993). Diet now appears to be
important in the genesis of several common cancers, although
the contribution of diet to total cancer incidence and
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mortality cannot be quantified on the basis of present
knowledge (WHO, 1990). The Scottish diet is typically low
in fruit, vegetable and fibre consumption and high in
saturated fat, refined sugar and salt intake (SHHD, 1993).
Given that dietary patterns are often established at a very
early age, it is likely that efforts to improve diet will be slow
to take effect.
The frequencies of cancers of the breast, ovary and
endometrium are influenced by past trends in reproductive
factors in the population, particularly those associated with
ovarian activity. Increased risk of breast cancer is
established in relation to early age at menarche, late
menopause, late age at first full-term pregnancy and low
parity. The last of these is also an important risk factor for
ovarian and endometrial cancer (Higginson et al., 1992).
Exogenous hormones also have a role in the aetiology of
female cancers. While there is conclusive evidence that use
of combined oral contraceptives protects against tumours of
the uterus and ovary (Tomatis, 1990), studies have suggested
that their use in adolescent women may result in a slight
increase in risk of breast cancer (UK National Case-
Control Study Group, 1989; Peto, 1989). In Scotland, the
birth rate declined from 88.0 per 1000 women aged 15-44
in 1975 to 57.8 per 1000 in 1993 and the mean age at first
pregnancy continues to rise (ISD, 1994). Data from the
Family Planning (Clinic) Services (ISD, 1994) indicate that,
in 1993, almost 50% fewer women using this service chose
oral contraceptives as a form of contraception than in 1975.
In the main, however, population-based data on trends in
most reproductive factors is either unavailable or limited.
Furthermore, the effects of such factors are likely to be
synergistic. It is therefore difficult to estimate the overall
impact that changes in these factors may have on the future
burden of cancer in Scotland.
Demographic change
Cancer is predominantly a disease of the elderly and the
majority of incident cases and deaths occur in persons older
than 65. It is projected, from the age-period-cohort
analyses, that the number of cancers diagnosed in those
aged 65-84 years will rise by 6% between 1986 and 2000,
compared with a fall of 3% for those aged under 65. A
sizeable increase (20%) in breast cancer cases in women in
the 65-84 age group (who are not routinely invited for
screening) is predicted, with a less than 10% reduction in
numbers of deaths. In addition, a large rise in numbers of
lung tumours diagnosed in women aged 65-84 is projected
(31%); the overall number oflung cancers in women aged up
to 84 years is forecast to rise by 8% between 1986 and 2000.
Demographic changes are likely to be an important
determinant of the future cancer burden. Growth in the
population at risk of the disease or changes in the population
structure (e.g. increasing proportions of older persons at
higher risk of developing or dying from cancer) may result in
increases in the number of cases or deaths even if the age-
specific risks do not alter, or indeed, fall. Between 1991
and 2001 increases of 15% and 12% in the population
aged 30-64 in Scotland are expected for males and females
respectively (Registrar General, 1993) with even greater
growth will be greatest in the numbers of very elderly. The
population aged 85 and older is forecast to double. Cancer is
likely to become a public health concern of increasing
dimensions in this age group.
Complementary nature of incidence and mortality data.
Several authors have reviewed the relative value of cancer
incidence and mortality data (e.g. Barker, 1984; Boyle,
1989). The routine availability of mortality data over many
years has meant that mortality rates have become the most
commonly used indicator of trends in cancer in human
populations. However, mortality rates are the product of
trends in both incidence of, and survival from, cancer.
Therefore, as survival for some cancers improves, the use of
mortality data in health monitoring becomes increasingly
inappropriate. This happens in two ways. First, greater
proportions of cancer patients who are treated successfully
and die of another cause will result in a fall in mortality
but not in the numbers of new patients seeking treatment
and using health care resources. Second, longer survival
times mean that mortality data reflect incidence of the
disease with an increasing delay which makes trends
difficult to interpret. Incidence data are the appropriate
indicators for predicting future needs for prevention and
early detection measures, diagnostic services and cancer
treatment facilities.
Primary prevention of cancer mortality
Mortality from cancer in a population may be influenced by
primary, secondary and tertiary prevention. Several of the
most common cancers are the result of many years of
cumulated exposure to carcinogens such as tobacco and
alcohol and less well understood risk factors such as lack of
intake of fresh fruit and vegetables (Higginson et al., 1992).
Primary prevention, instituted through programmes of
health promotion for example, is unlikely to effect an
immediate reduction in cancer mortality and represents a
long-term investment in improving the health of the
population.
Role of earlier diagnosis and therapy
For some cancers prognosis is directly related to the stage of
the disease at diagnosis (Ponten, 1991). Hence, mortality
may be influenced by detecting tumours earlier in their
natural history. Secondary prevention aims to promote
early diagnosis of disease, through, for example, systematic
screening programmes, health education campaigns, or
increased public awareness of cancer. Such initiatives,
however, may take some time to influence survival and
mortality rates. The thickness of malignant melanomas
diagnosed in the west of Scotland was significantly reduced
following a campaign promoting earlier reporting (MacKie
and Hole, 1992). However, since five year survival for
malignant melanoma for patients diagnosed in the mid-1980s
exceeded 70% (Black et al., 1993), it is likely to be some
time before mortality is affected. Similarly, the reduction in
mortality from cancer of the breast following the introduc-
tion of mammographic screening in Sweden took several
years to become apparent (Tabar et al., 1985). Improved
diagnostic techniques may also result in earlier diagnosis but
such advances are difficult to anticipate.
The introduction of effective therapy is the route most
likely to produce immediate and substantial reductions in
mortality from cancer. For example, in the mid-1970s when
combination chemotherapy utilising cisplatin was introduced
for the treatment of testicular cancer, mortality fell sharply
(Boyle et al., 1987). To date however, increased survival as a
direct result of advances in treatment has only been solidly
established for testicular tumours, some childhood and young
adult cancers (Birch et al., 1988; Hawkins, 1989) and
Hodgkin's disease (Boyle et al., 1988). Further developments
in treatment for the more common cancers are difficult to
predict. However, survival and, by extension, mortality may
also be influenced by the organisation and availability of
cancer diagnosis and treatment facilities. Studies have
suggested that patients treated at specialist centres or
teaching hospitals may have improved prognosis (Stiller,
1994; Harding et al., 1993; Gillis et al., 1991; Karjalainen,
1990). The use of treatment protocols, both within and
outwith clinical trials (Karjalainen and Palva, 1989) and
treatment by a specialist (Junor et al., 1994; McArdle and
Hole, 1991) have been shown to increase survival. Increasing
the proportion of patients offered the best available therapy
is likely to generate improvements in survival and, ultimately,
mortality rates. Such factors have begun to be addressed in
Scotland by the establishment ofthe Scottish Cancer Therapy
Network (Aitken et al., 1994).Progress Towards the Scottish Cancer Target
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Conclusion
The Scottish Cancer Target. established in 1991. proposed
that a reduction of 1500 in mortalitv from cancer in the
under-65s should be achieved betw-een 1986 and 2000. On the
basis of this analysis that target will be met. Mortality from
cancer in those under 65 y-ears of age between 1986 and 2000
in Scotland will fall bv 17%0 in men and 250o in women. In
contrast. however. it is projected that the number of new-
cancers diagnosed in this age group over the same time
period will decrease by 60o in men but remain constant in
women. W`e regret that the cancer tarzet published for
Scotland addresses only one aspect of cancer control. namelv
mortalitv. Without examination of the interplay between
incidence and mortality it is impossible to obtain a sound
understanding of the situation. Cancer control demands such
an integrated approach.
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